Quoin Pharmaceuticals (NASDAQ:QNRX) Posts Quarterly Earnings Results, Beats Estimates By $0.15 EPS

Quoin Pharmaceuticals (NASDAQ:QNRX) issued its quarterly earnings results on Thursday. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.15, Zacks reports.

Quoin Pharmaceuticals Stock Down 0.5 %

Quoin Pharmaceuticals stock opened at $0.30 on Thursday. The company has a fifty day simple moving average of $0.41 and a 200-day simple moving average of $0.56. The firm has a market capitalization of $1.50 million, a price-to-earnings ratio of -0.07 and a beta of 1.82. Quoin Pharmaceuticals has a 52-week low of $0.27 and a 52-week high of $1.57.

Insider Transactions at Quoin Pharmaceuticals

In related news, Director Anthony James Culverwell purchased 100,000 shares of the business’s stock in a transaction that occurred on Monday, December 23rd. The stock was purchased at an average price of $0.45 per share, with a total value of $45,000.00. Following the completion of the acquisition, the director now owns 100,317 shares in the company, valued at $45,142.65. This trade represents a 31,545.74 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Gordon Dunn acquired 122,221 shares of Quoin Pharmaceuticals stock in a transaction that occurred on Monday, December 23rd. The shares were bought at an average price of $0.45 per share, for a total transaction of $54,999.45. Following the transaction, the chief financial officer now owns 151,077 shares of the company’s stock, valued at $67,984.65. This represents a 423.55 % increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 777,777 shares of company stock valued at $350,000. Corporate insiders own 3.70% of the company’s stock.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.